Aitua Ltd (“Aitua”), the life science IP commercialisation company, today announces that one of its portfolio companies, Probe Scientific (“Probe”), the medical device company, has been awarded regulatory approval to market its MicroEye® device in Europe. MicroEye® is a sterile single-use, minimally invasive blood sampling device which allows continuous blood sampling in collaboration with pre-existing access devices, thereby avoiding repeated needle puncture for the patient.
